Finanzen von NewAmsterdam Pharma Company NV (NAMS)NAMSNewAmsterdam Pharma Company NV

Evaluating the bottom line, NewAmsterdam Pharma Company N.V. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1752.61%, while the net margin is -1732.91%. These profitability ratios, combined with a Return on Equity (ROE) of -36.81%, provide a clear picture of how effectively NAMS converts its operational activities into shareholder value.

In the context of the broader market, NAMS competes directly with industry leaders such as PBH and PRGO. With a market capitalization of $2.36B, it holds a leading position in the sector. When comparing efficiency, NAMS's gross margin of 100.00% stands against PBH's 49.11% and PRGO's 30.69%. Such benchmarking helps identify whether NewAmsterdam Pharma Company N.V. is trading at a premium or discount relative to its financial performance.

NewAmsterdam Pharma has shown declining revenues, with Q2 2026 revenue at $3.7 million, an 80.7% year-over-year decline. The net income for Q2 2026 was a loss of $64.1 million, indicating ongoing financial struggles.